MET and hepatocellular carcinoma: In HCC patients, concurrent activation of c-Met and β-catenin gene mutations was observed in 9%–12.5% of samples; additionally, co-activation of c-Met and Axin1 loss-of-function mutations was found in approximately 3%–5% of samples.